Announcements Trials
Browse Landscape

Phase

Phase 3 9Phase 2 7Phase 1/2 6Phase 1 6Phase 4 1

Status

Completed 4Recruiting 2Withdrawn 1

Sponsor Class

OTHER 67INDUSTRY 7OTHER_GOV 3UNKNOWN 2

Study Type

Interventional 7

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 3Other solid neoplasm 1

Conditions

Colorectal Neoplasms 3NSCLC 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1

Interventions

Carboplatin 272Paclitaxel 267Gemcitabine 244Bevacizumab 225Cisplatin 216pembrolizumab 213Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 99Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 80Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Ipilimumab 64Bortezomib 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × HMPL-013 × Clear all
NCT07235293 2026-05-22

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

Kahr Medical

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06992258 2026-03-17

FRUITION

Criterium, Inc.

Phase 2 Recruiting
120 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT04716634 2025-03-25

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

BeiGene

Phase 2 Completed
84 enrolled 17 charts
Other solid neoplasm

Advanced Solid Tumors

NCT02196688 2020-06-16

Study of Fruquintinib in Patients With Metastatic Colorectal Cancer

Hutchmed

Phase 2 Completed
71 enrolled 13 charts
Gastrointestinal

Colorectal Neoplasms

NCT02590965 2020-02-13

A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer

Hutchmed

Phase 2 Completed
91 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03684967 2019-11-19

Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC

Hutchmed

Phase 2 Withdrawn
Thoracic

Lung Neoplasms

NCT02976116 2019-11-15

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Hutchmed

Phase 2 Completed
50 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡